Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT1812 pilot study in mild to moderate Alzheimer's disease
2018-000163-89Phase 2Terminated
- Sponsor
- Cognition Therapeutics, Inc.
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zervimesine in Alzheimer's disease (AD) (3 arms), sponsored by Cognition Therapeutics, Inc. Primary endpoint: Change from baseline in CSF amyloid-beta oligomer concentration after dosing with CT1812 versus placebo. Started Mar 2018; status: terminated.
02
Drugs
zervimesine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2018-000163-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000163-89.